Adolor to Host Conference Call on May 14, 2003 to Discuss First Quarter 2003 Financial Results and Provide a Product Development Program Update.

Business Editors

EXTON, Pa.--(BUSINESS WIRE)--May 7, 2003

Adolor Corporation (Nasdaq: ADLR) will host a conference call on Wednesday, May 14, 2003 at 5:00 p.m. EDT to discuss the Company's financial results for the first quarter and provide a product development program update.

Adolor will announce its financial results for this period in a press release to be issued at approximately 4:00 p.m. EDT on May 14, 2003.

The conference call may be accessed by dialing 800/915-4836 for domestic callers and 973/317-5319 for international callers. The call will also be webcast on the investor relations section of Adolor's website at www.adolor.com and archived on the site until May 21, 2003.

A replay of the conference call will be available from 7:00 p.m. EDT on May 14, 2003 through 11:59 p.m. EDT on May 21, 2003, and may be accessed by visiting Adolor's website or by dialing 800/428-6051 for domestic callers and 973/709-2089 for international callers. The replay access code is 293096.

About Adolor Corporation

Adolor Corporation is a development stage biopharmaceutical company engaged in the development of proprietary pharmaceutical products for the treatment of pain and the side effects that are caused by current pain treatments. The Company has a number of small molecule product candidates that are in various stages of development ranging from preclinical studies to Phase 3 clinical trials.

Adolor's lead product candidate, alvimopan, is designed to selectively block the unwanted effects of opioid analgesics on the gastrointestinal tract. Alvimopan is a potential first-in-class compound that is being evaluated in acute and chronic indications, including management of postoperative ileus and for the treatment of bowel dysfunction associated with the chronic use of opioids.

In April 2002, Adolor entered into a collaboration agreement with GlaxoSmithKline for the exclusive worldwide development and commercialization of alvimopan for certain indications.

This release, and oral statements made with respect to information contained in this release, constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include those which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact.

These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements.

Such known risks and uncertainties relate to, among other factors: Adolor's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Adolor's product candidates, including alvimopan, may not be successful; the risk that Adolor may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, or otherwise; Adolor's reliance on its collaborators, including Glaxo Group Limited, in connection with the development and commercialization of Adolor's product candidates; market acceptance of Adolor's products, if regulatory approval is achieved; competition; and other risk factors detailed from time to time in reports filed by Adolor with the Securities and Exchange Commission.

Further information about these and other relevant risks and uncertainties may be found in Adolor's filings with the SEC, including but not limited to Adolor's Report on Form 10-K for the year ended December 31, 2002 filed March 18, 2003.

We urge you to carefully review and consider the disclosures found in that filing which is available in the SEC EDGAR database at www.sec.gov and from Adolor at www.adolor.com.

Given the uncertainties affecting pharmaceutical companies in the development stage, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors.

Adolor undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.

This press release is available on the website http://www.adolor.com.